Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1010 + mRNA-1273
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1010 + mRNA-1273 (also known by the development code mRNA-1073) is an investigational combination vaccine developed by Moderna, Inc. to provide simultaneous protection against seasonal influenza and COVID-19. The vaccine consists of mRNA-1010, a quadrivalent influenza candidate targeting the hemagglutinin (HA) proteins of A/H1N1, A/H3N2, B/Victoria, and B/Yamagata strains, and mRNA-1273 (Spikevax), which targets the SARS-CoV-2 spike protein. Both components are encapsulated in lipid nanoparticles (LNPs) for efficient delivery and expression in host cells. This combination aims to reduce the global burden of respiratory diseases and simplify vaccination schedules through a single injection. It is also a component of Moderna's triple combination vaccine candidate, mRNA-1230.
- Other names
- mRNA-1010/mRNA-1273Moderna COVID-19 + Flu vaccine
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1010 + mRNA-1273.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1010 + mRNA-1273.